These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3185919)

  • 21. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M; Santens P; Van Borsel J
    J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
    Dubois B; Pilon B; Lhermitte F; Agid Y
    Ann Neurol; 1990 Aug; 28(2):117-21. PubMed ID: 2221841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise.
    Goetz CG; Thelen JA; MacLeod CM; Carvey PM; Bartley EA; Stebbins GT
    Neurology; 1993 May; 43(5):1040-2. PubMed ID: 8492923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.
    Alexander GM; Schwartzman RJ; Nukes TA; Grothusen JR; Hooker MD
    Neurology; 1994 Aug; 44(8):1511-3. PubMed ID: 8058159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease: long-term results of levodopa therapy.
    Pentland B; Matthews D; Mawdsley C
    Scott Med J; 1982 Oct; 27(4):284-7. PubMed ID: 7146876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nosography of Parkinson's disease.
    Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1986; 22():119-28. PubMed ID: 3465866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
    Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 32. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM; Gandy SE; McDowell FH
    Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Levodopa on Vowel Articulation in Patients with Parkinson's Disease.
    Okada Y; Murata M; Toda T
    Kobe J Med Sci; 2015 Apr; 61(5):E144-54. PubMed ID: 27363398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upper airway muscles dysfunction and levodopa responsiveness in Parkinson's disease.
    Brescia Morra V; Polverino M; De Luca G; Landi P; Galdi A; Campanella G
    Acta Neurol (Napoli); 1992; 14(4-6):512-8. PubMed ID: 1293993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yawning as an aura for an L-dopa-induced "on" in Parkinson's disease.
    Goren JL; Friedman JH
    Neurology; 1998 Mar; 50(3):823. PubMed ID: 9521290
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prosodic expression and levodopa in Parkinson's disease.
    Behlau M
    Arq Neuropsiquiatr; 2013 Nov; 71(11):831-2. PubMed ID: 24394865
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excitability of the lower-limb area of the motor cortex in Parkinson's disease.
    Vacherot F; Attarian S; Eusebio A; Azulay JP
    Neurophysiol Clin; 2010 Aug; 40(4):201-8. PubMed ID: 20674816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.